|
Deal's going round the world |
|
|
|
|
Dr. Reddy's Laboratories
Pfizer
Bioaccelerate Holdings
Laboratory Corp. of America
Dainippon Pharmaceutical Dealing the Deal's
|
DEAL WATCH |
|
WHO |
WITH |
WHAT |
SCOOP |
Laboratory Corp. of America
Burlington, NC |
Esoterix
Austin, TX |
$150 million cash buyout
|
Lab Corp gains nine new laboratories specializing in testing for hospitals,
specialty physicians, pharmaceutical and biotechnology companies,
laboratories and managed care organizations. |
Organic
Soils.com
Anchorage, AL |
Inhibetex Therapeutics
|
All-stock acquisition |
The new company will go after cancer research in a big way, first focusing
on a protocol to investigate the effect of PKC isozymes on the regulation of
brain cancer cells. |
Dr. Reddy's Laboratories
India |
ICICI Ventures
India |
$56M partnership |
ICICI is funding the development and legal costs surrounding Dr. Reddy's new
round of ANDAs. |
Pfizer
New York City |
Coley Pharmaceutical
Wellesley, MA |
Licensing deals |
Pfizer paying Coley up to $505 million for licensing deal covering Coley's
ProMune cancer treatment. |
Bioaccelerate Holdings
New York City |
Supratek Pharma
Montreal, Canada |
$5 million research investment |
Bioaccelerate is backing research into Supratek's SP1049C, a therapy for
solid tumors, malignant lymphomas, leukemias, soft tissue sarcoma, GI, and
refractory breast cancer. |
Dainippon Pharmaceutical
Japan |
Zoegene
Japan |
Joint research pact |
Working with Zoegene's compounds, Dainippon Pharmaceutical will conduct
further research in order to synthesize a candidate compound for
anti-obesity and antidiabetic drugs with a new action mechanism. |
EntreMed
Rockville, MD |
Celgene
Summit, NJ |
Commercialization pact |
EntreMed granted rights to commercialize Celgene's tubulin inhibitor
compounds cancer therapy. |
Source:www
|
|
Last Updated ( Friday, 01 April 2005 )
|
